Diseases /
Head and Neck Squamous Cell Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands. [1]
Head and neck squamous cell carcinomas most frequently harbor alterations in TP53, CDKN2A, PIK3CA, NOTCH1, and KMT2D [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, PIK3CA Mutation, and CDKN2A Mutation are the most common alterations in head and neck squamous cell carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for head and neck squamous cell carcinoma, 1 is FDA-approved in at least one setting and 1 has NCCN guidelines in at least one setting [3].
Pembrolizumab +
Disease is predicted to be sensitive: -
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
Note: Approved as a single agent for the first line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1]. |
Clinical Trials
There are 357 clinical trials for head and neck squamous cell carcinoma, of which 281 are open and 76 are completed or closed. Of the trials that contain head and neck squamous cell carcinoma as an inclusion criterion, 6 are early phase 1 (4 open), 140 are phase 1 (104 open), 78 are phase 1/phase 2 (63 open), 120 are phase 2 (101 open), 1 is phase 2/phase 3 (0 open), 9 are phase 3 (7 open), 1 is phase 4 (1 open), and 2 are no phase specified (1 open).
HPV, CDKN2A, and PD-L1 are the most frequent gene inclusion criteria for head and neck squamous cell carcinoma clinical trials [3].
Pembrolizumab, nivolumab, and cetuximab are the most common interventions in head and neck squamous cell carcinoma clinical trials.
Significant Genes in Head and Neck Squamous Cell Carcinoma
AKT1 +
AKT1 is altered in 1.36% of head and neck squamous cell carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain AKT1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].
AKT2 +
AKT2 is altered in 1.71% of head and neck squamous cell carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
AKT3 +
AKT3 is altered in 1.33% of head and neck squamous cell carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
ALK +
ALK is altered in 3.34% of head and neck squamous cell carcinoma patients [2].
ALK is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is altered in 5.83% of head and neck squamous cell carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ATM +
ATM is altered in 4.45% of head and neck squamous cell carcinoma patients [2].
ATM is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].
ATR +
ATR is altered in 6.04% of head and neck squamous cell carcinoma patients [2].
ATR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ATRX +
ATRX is altered in 3.22% of head and neck squamous cell carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATRX status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
AXL +
AXL is altered in 1.97% of head and neck squamous cell carcinoma patients [2].
AXL is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
BARD1 +
BARD1 is altered in 1.31% of head and neck squamous cell carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
BCL2 +
BCL2 is altered in 0.3% of head and neck squamous cell carcinoma patients [2].
BCL2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BCL6 +
BCL6 is altered in 3.98% of head and neck squamous cell carcinoma patients [2].
BCL6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BIRC2 +
BIRC2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BIRC3 +
BIRC3 is altered in 3.52% of head and neck squamous cell carcinoma patients [2].
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
BRAF +
BRAF is altered in 1.55% of head and neck squamous cell carcinoma patients [2].
BRAF is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRAF status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
BRCA1 +
BRCA1 is altered in 4.18% of head and neck squamous cell carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].
BRCA2 +
BRCA2 is altered in 6.06% of head and neck squamous cell carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].
BRIP1 +
BRIP1 is altered in 2.23% of head and neck squamous cell carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRIP1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.57% of head and neck squamous cell carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain C11orf30 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
CARD11 +
CARD11 is altered in 2.6% of head and neck squamous cell carcinoma patients [2].
CARD11 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CCND1 +
CCND1 is altered in 11.58% of head and neck squamous cell carcinoma patients [2].
CCND1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CD79A +
CD79A is altered in 0.58% of head and neck squamous cell carcinoma patients [2].
CD79A is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CD79B +
CD79B is altered in 0.4% of head and neck squamous cell carcinoma patients [2].
CD79B is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 2.53% of head and neck squamous cell carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
CDK4 +
CDK4 is altered in 0.75% of head and neck squamous cell carcinoma patients [2].
CDK4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CDK6 +
CDK6 is altered in 1.83% of head and neck squamous cell carcinoma patients [2].
CDK6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CDKN2A +
CDKN2A is altered in 23.69% of head and neck squamous cell carcinoma patients [2].
CDKN2A is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDKN2A status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].
CHEK1 +
CHEK1 is altered in 0.53% of head and neck squamous cell carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
CHEK2 +
CHEK2 is altered in 1.52% of head and neck squamous cell carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
CRKL +
CRKL is altered in 1.17% of head and neck squamous cell carcinoma patients [2].
CRKL is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CRKL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
DDR2 +
DDR2 is altered in 2.37% of head and neck squamous cell carcinoma patients [2].
DDR2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is altered in 6.43% of head and neck squamous cell carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 2.81% of head and neck squamous cell carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ERBB2 status and head and neck squamous cell carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].
ERBB3 +
ERBB3 is altered in 3.31% of head and neck squamous cell carcinoma patients [2].
ERBB3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB4 +
ERBB4 is altered in 4.21% of head and neck squamous cell carcinoma patients [2].
ERBB4 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 2.05% of head and neck squamous cell carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ERCC3 +
ERCC3 is altered in 1.41% of head and neck squamous cell carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ERCC4 +
ERCC4 is altered in 2.44% of head and neck squamous cell carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 1.81% of head and neck squamous cell carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC5 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
ERCC6 +
ERCC6 is altered in 0.92% of head and neck squamous cell carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCA +
FANCA is altered in 3.09% of head and neck squamous cell carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCA status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCB +
FANCB is altered in 2.26% of head and neck squamous cell carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCB status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCC +
FANCC is altered in 0.77% of head and neck squamous cell carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCC status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCD2 +
FANCD2 is altered in 2.66% of head and neck squamous cell carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCD2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCE +
FANCE is altered in 1.01% of head and neck squamous cell carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCF +
FANCF is altered in 1.2% of head and neck squamous cell carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCF status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCG +
FANCG is altered in 0.68% of head and neck squamous cell carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCG status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCI +
FANCI is altered in 3.4% of head and neck squamous cell carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCI status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCL +
FANCL is altered in 2.49% of head and neck squamous cell carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCL status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FANCM +
FANCM is altered in 6.21% of head and neck squamous cell carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCM status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
FGFR1 +
FGFR1 is altered in 2.38% of head and neck squamous cell carcinoma patients [2].
FGFR1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].
FGFR2 +
FGFR2 is altered in 1.85% of head and neck squamous cell carcinoma patients [2].
FGFR2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].
FGFR3 +
FGFR3 is altered in 3.25% of head and neck squamous cell carcinoma patients [2].
FGFR3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
HRAS +
HRAS is altered in 3.51% of head and neck squamous cell carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain HRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
KDR +
KDR is altered in 3.08% of head and neck squamous cell carcinoma patients [2].
KDR is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
KIT +
KIT is altered in 1.89% of head and neck squamous cell carcinoma patients [2].
KIT is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
KRAS +
KRAS is altered in 2.52% of head and neck squamous cell carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 5 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 2 are closed. Of the trials that contain KRAS status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MCPH1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MDM2 +
MDM2 is altered in 1.4% of head and neck squamous cell carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MDM4 +
MDM4 is altered in 0.77% of head and neck squamous cell carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MET +
MET is altered in 2.75% of head and neck squamous cell carcinoma patients [2].
MET is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is altered in 0.56% of head and neck squamous cell carcinoma patients [2].
MLF1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MLH1 +
MLH1 is altered in 1.7% of head and neck squamous cell carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MLH3 +
MLH3 is altered in 3.28% of head and neck squamous cell carcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLH3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MRE11A +
MRE11A is altered in 1.19% of head and neck squamous cell carcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MRE11A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MSH2 +
MSH2 is altered in 1.84% of head and neck squamous cell carcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MSH3 +
MSH3 is altered in 1.52% of head and neck squamous cell carcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MSH6 +
MSH6 is altered in 2.31% of head and neck squamous cell carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MTAP +
MTAP is altered in 0.75% of head and neck squamous cell carcinoma patients [2].
MTAP is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MTOR +
MTOR is altered in 3.63% of head and neck squamous cell carcinoma patients [2].
MTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
MUTYH +
MUTYH is altered in 0.89% of head and neck squamous cell carcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MUTYH status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
MYC +
MYC is altered in 2.32% of head and neck squamous cell carcinoma patients [2].
MYC is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
NBN +
NBN is altered in 1.85% of head and neck squamous cell carcinoma patients [2].
NBN is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
NFKBIA +
NFKBIA is altered in 2.55% of head and neck squamous cell carcinoma patients [2].
NFKBIA is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
NOTCH1 +
NOTCH1 is altered in 16.36% of head and neck squamous cell carcinoma patients [2].
NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
NPM1 +
NPM1 is altered in 0.37% of head and neck squamous cell carcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
NRAS +
NRAS is altered in 1.36% of head and neck squamous cell carcinoma patients [2].
NRAS is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain NRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [3].
NTRK1 +
NTRK1 is altered in 3.06% of head and neck squamous cell carcinoma patients [2].
NTRK1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
NTRK2 +
NTRK2 is altered in 1.71% of head and neck squamous cell carcinoma patients [2].
NTRK2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
NTRK3 +
NTRK3 is altered in 2.72% of head and neck squamous cell carcinoma patients [2].
NTRK3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
PALB2 +
PALB2 is altered in 2.05% of head and neck squamous cell carcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PARP1 +
PARP1 is altered in 0.43% of head and neck squamous cell carcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PDGFRA +
PDGFRA is altered in 2.26% of head and neck squamous cell carcinoma patients [2].
PDGFRA is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PDGFRA status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
PIK3AP1 +
PIK3AP1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3AP1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
PIK3CA +
PIK3CA is altered in 21.01% of head and neck squamous cell carcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain PIK3CA status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].
PIK3CG +
PIK3CG is altered in 2.43% of head and neck squamous cell carcinoma patients [2].
PIK3CG is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CG status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
PIK3R1 +
PIK3R1 is altered in 1.91% of head and neck squamous cell carcinoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
PIK3R2 +
PIK3R2 is altered in 1.23% of head and neck squamous cell carcinoma patients [2].
PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
PIK3R5 +
PIK3R5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
PMS1 +
PMS1 is altered in 1.5% of head and neck squamous cell carcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PMS1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PMS2 +
PMS2 is altered in 2.05% of head and neck squamous cell carcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PMS2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
POLE +
POLE is altered in 3.65% of head and neck squamous cell carcinoma patients [2].
POLE is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 0.83% of head and neck squamous cell carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R1A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R2A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
PTEN +
PTEN is altered in 6.31% of head and neck squamous cell carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 4 are closed. Of the trials that contain PTEN status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [3].
RAD50 +
RAD50 is altered in 1.74% of head and neck squamous cell carcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RAD51 +
RAD51 is altered in 0.4% of head and neck squamous cell carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RAD51C +
RAD51C is altered in 1.45% of head and neck squamous cell carcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51C status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RAD51D +
RAD51D is altered in 0.73% of head and neck squamous cell carcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RAD54L +
RAD54L is altered in 0.42% of head and neck squamous cell carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
RET +
RET is altered in 2.58% of head and neck squamous cell carcinoma patients [2].
RET is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RICTOR +
RICTOR is altered in 2.65% of head and neck squamous cell carcinoma patients [2].
RICTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RICTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
RNF43 +
RNF43 is altered in 1.87% of head and neck squamous cell carcinoma patients [2].
RNF43 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RPTOR +
RPTOR is altered in 1.74% of head and neck squamous cell carcinoma patients [2].
RPTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RPTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
SLX4 +
SLX4 is altered in 3.45% of head and neck squamous cell carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SLX4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 0.74% of head and neck squamous cell carcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 1.83% of head and neck squamous cell carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain STAG2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
STK11 +
STK11 is altered in 2.08% of head and neck squamous cell carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain STK11 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
TNFAIP3 +
TNFAIP3 is altered in 1.05% of head and neck squamous cell carcinoma patients [2].
TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TP53 +
TP53 is altered in 48.34% of head and neck squamous cell carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain TP53 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
TSC1 +
TSC1 is altered in 2.08% of head and neck squamous cell carcinoma patients [2].
TSC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
TSC2 +
TSC2 is altered in 3.47% of head and neck squamous cell carcinoma patients [2].
TSC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
XRCC1 +
XRCC1 is altered in 2.82% of head and neck squamous cell carcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain XRCC1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.